David de Graaf has a new gig, a new idea and a new start­up — hunt­ing some new mon­ey

David de Graaf has a new gig at the helm of a tiny biotech start­up. And he has some big plans to pur­sue an un­usu­al path­way in drug de­vel­op­ment.

You may re­mem­ber that de Graaf had been CEO at Syn­tim­mune, leav­ing the com­pa­ny short­ly be­fore Alex­ion swooped in and bought the rare-dis­ease biotech for $1.2 bil­lion. Last fall, he stepped up to take charge of a small com­pa­ny in the Nether­lands. 

In short or­der, he changed the name to Comet and set up a new HQ in Cam­bridge, MA — 3 of the 5-mem­ber start­up team are still in the Nether­lands — and now the ex-Ap­ple Tree part­ner has hit the cir­cuit look­ing to raise a launch round for his new en­deav­or, with plans to boost the staff to about 20 peo­ple.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.